NewAmsterdam Pharma Company NAMS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $457.61M-38.9% | $490M-36.5% | $538.41M+27.4% | $563.86M+30.9% | $748.42M+55.5% | ||
| $178.5M+197% | $146.24M+134% | $164.54M— | $175.3M— | $60.06M— | ||
| $658.04M-19.5% | $675.7M-21.7% | $732.33M+67.2% | $769.85M+72.9% | $817.3M+67.5% | ||
| $379K+59.2% | $383K+58.3% | $323K+39.8% | $312K+33.3% | $238K+136% | ||
| $375K-25.3% | $407K-23.8% | $439K-26.0% | $470K-13.3% | $502K+3.3% | ||
| $732.64M-10.5% | $769.28M-11.0% | $786.43M+79.1% | $815.11M+82.5% | $818.41M+67.5% | ||
| $8.09M+32.9% | $8.97M+89.1% | $3.63M-48.4% | $5.9M+11.8% | $6.09M-28.7% | ||
| $3.99M+31.6% | $3.99M-33.6% | —— | —— | $3.03M+582% | ||
| $67.42M+64.8% | $85.79M-19.8% | $58.27M+41.2% | $36.51M-19.4% | $40.91M-31.5% | ||
| $67.42M+64.2% | $85.85M-19.9% | $58.36M-3.3% | $36.62M-38.2% | $41.05M-46.5% | ||
| $14.59M+4.5% | $14.28M+6.2% | $14.11M+23.4% | $14.01M+25.7% | $13.97M+25.7% | ||
| -$810.83M-35.6% | -$762.39M-36.5% | -$687.47M-47.4% | -$615.46M-36.8% | -$598.1M-45.6% | ||
| $665.22M-14.4% | $683.43M-9.8% | $728.07M+92.2% | $778.5M+101% | $777.36M+88.8% | ||
| $732.64M-10.5% | $769.28M-11.0% | $786.43M+79.1% | $815.11M+82.5% | $818.41M+67.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NewAmsterdam Pharma Company's total assets?
- NewAmsterdam Pharma Company (NAMS) holds $732.6M in total assets, down 10.5% year over year.
- How much debt does NewAmsterdam Pharma Company have?
- NewAmsterdam Pharma Company carries $23.0K in total debt against $665.2M of shareholders' equity.
- How much cash does NewAmsterdam Pharma Company have?
- NewAmsterdam Pharma Company holds $457.6M in cash and equivalents.
- Can NewAmsterdam Pharma Company cover its short-term obligations?
- Its current ratio is 9.76 — current assets exceed current liabilities.
- Where does NewAmsterdam Pharma Company's balance sheet data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
